ViiV expands license to produce generic Apretude in low-income countries

ViiV Healthcare, which is majority owned by GSK (NYSE:GSK), said it will expand a licensing agreement with the Medicines Patent Pool that will allow manufacturers to produce generic Apretude (cabotegravir) for low-income countries as a long-acting HIV treatment.
Previously, the agreement only allowed for generic cabotegravir production for HIV prevention.
Existing licensees are Aurobindo, Cipla, and Viatris (NASDAQ:VTRS).
Generic Apretude should be used in combination with Johnson & Johnson’s (JNJ) Edurant (rilpivirine), ViiV stated.
Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY)(OTCPK:SGIOF) are minority shareholders in ViiV.

More on GSK